| Trial ID: | L2992 |
| Source ID: | NCT00481429
|
| Associated Drug: |
Rosiglitazone
|
| Title: |
Predictive Markers of Glitazone Efficacy in Diabetic Patients - Pilot Study
|
| Acronym: |
|
| Status: |
WITHDRAWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Rosiglitazone
|
| Outcome Measures: |
Primary: The performance of baseline biochemical biomarkers in plasma and urine in distinguishing patients who respond to rosiglitazone from those that do not, as classified by a change in HbA1C at 12 weeks., 12 weeks | Secondary: Variability in baseline levels of key biochemical markers in diabetic patients., 12 weeks|Effect of treatment on a variety of other novel potential predictive biomarkers and markers of insulin sensitisation in diabetic patients., 12 weeks
|
| Sponsor/Collaborators: |
Sponsor: Imperial College London | Collaborators: GlaxoSmithKline
|
| Gender: |
MALE
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
0
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2007-05
|
| Completion Date: |
2008-01
|
| Results First Posted: |
|
| Last Update Posted: |
2019-07-10
|
| Locations: |
Addenbrooke's Hospital, Cambridge, CB2 2GG, United Kingdom|Ealing Hospital, London, UB1 3HW, United Kingdom|Imperial College London - Hammersmith Campus, London, W12 ONN, United Kingdom|Charing Cross Hospital, London, W6 8RF, United Kingdom
|
| URL: |
https://clinicaltrials.gov/show/NCT00481429
|
